{"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}],"groups":[{"description":"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter). Participants also received 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23.\n\nParticipants received treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, subject noncompliance, or intercurrent illness or worsening of a chronic condition, whichever occurred first.","id":"BG000","title":"Carfilzomib With Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.4","value":"59.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"67"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"}],"title":"Asian"}],"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68"}],"title":"0 (Fully active)"},{"measurements":[{"groupId":"BG000","value":"45"}],"title":"1 (Restricted but ambulatory)"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"2 (Ambulatory but unable to work)"}],"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}]}],"description":"A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care, unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.4","upperLimit":"182.8","value":"38.70"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"117"}],"units":"Participants"}]}],"description":"One participant had a data entry error with year of diagnosis entered as 2017 instead of 2014, leading to an erroneous minimum time since diagnosis reported.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Participants with available data","title":"Time From Initial Diagnosis to First Dose","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"19","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"123"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Total Number of Prior Regimens","unitOfMeasure":"regimens"}],"populationDescription":"The safety population consisted of all enrolled participants who received at least 1 dose of carfilzomib."}